Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia

A randomized, double-blind, sham-controlled study

Anushree Bose, Venkataram Shivakumar, Sri Mahavir Agarwal, Sunil V. Kalmady, Sonia Shenoy, Vanteemar S. Sreeraj, Janardhanan C. Narayanaswamy, Ganesan Venkatasubramanian

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20-30% of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on treatment for refractory AVH in schizophrenia. Studies examining the efficacy of tDCS for refractory AVH in schizophrenia have reported inconsistent findings. In this study, using a randomized, double-blind, sham-controlled design (RCT), we sought to examine the effect of add-on tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5-days] to treat refractory AVH in schizophrenia patients (N = 25); following this RCT phase, patients that had <. 30% reduction in AVH severity were offered an open-label extension (OLE) active stimulation to evaluate the effect of cross-over to verum tDCS. In the RCT phase, repeated measures ANOVA with tDCS type [verum (N = 12) vs. sham (N = 13)] as between subjects factor demonstrated a significant tDCS-type X time-point interaction [F = 21.5, p. <. 0.001, partial-η2 = 0.48] with significantly greater reduction of AVH score in verum tDCS group as compared to sham group. In the OLE phase, sham-to-verum crossed over patients (N = 13) showed significantly greater reduction in AVH severity than their corresponding change during RCT phase (t = 2.9; p = 0.01). Together, these observations add further support to the beneficial effects of add-on tDCS to treat refractory AVH schizophrenia.

Original languageEnglish
JournalSchizophrenia Research
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Hallucinations
Schizophrenia
Electrodes
Transcranial Direct Current Stimulation
Prefrontal Cortex
Antipsychotic Agents
Analysis of Variance

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Bose, Anushree ; Shivakumar, Venkataram ; Agarwal, Sri Mahavir ; Kalmady, Sunil V. ; Shenoy, Sonia ; Sreeraj, Vanteemar S. ; Narayanaswamy, Janardhanan C. ; Venkatasubramanian, Ganesan. / Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia : A randomized, double-blind, sham-controlled study. In: Schizophrenia Research. 2018.
@article{5c04cce2cdb64423b706a44ff45045f8,
title = "Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia: A randomized, double-blind, sham-controlled study",
abstract = "Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20-30{\%} of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on treatment for refractory AVH in schizophrenia. Studies examining the efficacy of tDCS for refractory AVH in schizophrenia have reported inconsistent findings. In this study, using a randomized, double-blind, sham-controlled design (RCT), we sought to examine the effect of add-on tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5-days] to treat refractory AVH in schizophrenia patients (N = 25); following this RCT phase, patients that had <. 30{\%} reduction in AVH severity were offered an open-label extension (OLE) active stimulation to evaluate the effect of cross-over to verum tDCS. In the RCT phase, repeated measures ANOVA with tDCS type [verum (N = 12) vs. sham (N = 13)] as between subjects factor demonstrated a significant tDCS-type X time-point interaction [F = 21.5, p. <. 0.001, partial-η2 = 0.48] with significantly greater reduction of AVH score in verum tDCS group as compared to sham group. In the OLE phase, sham-to-verum crossed over patients (N = 13) showed significantly greater reduction in AVH severity than their corresponding change during RCT phase (t = 2.9; p = 0.01). Together, these observations add further support to the beneficial effects of add-on tDCS to treat refractory AVH schizophrenia.",
author = "Anushree Bose and Venkataram Shivakumar and Agarwal, {Sri Mahavir} and Kalmady, {Sunil V.} and Sonia Shenoy and Sreeraj, {Vanteemar S.} and Narayanaswamy, {Janardhanan C.} and Ganesan Venkatasubramanian",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.schres.2017.08.047",
language = "English",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia : A randomized, double-blind, sham-controlled study. / Bose, Anushree; Shivakumar, Venkataram; Agarwal, Sri Mahavir; Kalmady, Sunil V.; Shenoy, Sonia; Sreeraj, Vanteemar S.; Narayanaswamy, Janardhanan C.; Venkatasubramanian, Ganesan.

In: Schizophrenia Research, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of fronto-temporal transcranial direct current stimulation for refractory auditory verbal hallucinations in schizophrenia

T2 - A randomized, double-blind, sham-controlled study

AU - Bose, Anushree

AU - Shivakumar, Venkataram

AU - Agarwal, Sri Mahavir

AU - Kalmady, Sunil V.

AU - Shenoy, Sonia

AU - Sreeraj, Vanteemar S.

AU - Narayanaswamy, Janardhanan C.

AU - Venkatasubramanian, Ganesan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20-30% of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on treatment for refractory AVH in schizophrenia. Studies examining the efficacy of tDCS for refractory AVH in schizophrenia have reported inconsistent findings. In this study, using a randomized, double-blind, sham-controlled design (RCT), we sought to examine the effect of add-on tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5-days] to treat refractory AVH in schizophrenia patients (N = 25); following this RCT phase, patients that had <. 30% reduction in AVH severity were offered an open-label extension (OLE) active stimulation to evaluate the effect of cross-over to verum tDCS. In the RCT phase, repeated measures ANOVA with tDCS type [verum (N = 12) vs. sham (N = 13)] as between subjects factor demonstrated a significant tDCS-type X time-point interaction [F = 21.5, p. <. 0.001, partial-η2 = 0.48] with significantly greater reduction of AVH score in verum tDCS group as compared to sham group. In the OLE phase, sham-to-verum crossed over patients (N = 13) showed significantly greater reduction in AVH severity than their corresponding change during RCT phase (t = 2.9; p = 0.01). Together, these observations add further support to the beneficial effects of add-on tDCS to treat refractory AVH schizophrenia.

AB - Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20-30% of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on treatment for refractory AVH in schizophrenia. Studies examining the efficacy of tDCS for refractory AVH in schizophrenia have reported inconsistent findings. In this study, using a randomized, double-blind, sham-controlled design (RCT), we sought to examine the effect of add-on tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5-days] to treat refractory AVH in schizophrenia patients (N = 25); following this RCT phase, patients that had <. 30% reduction in AVH severity were offered an open-label extension (OLE) active stimulation to evaluate the effect of cross-over to verum tDCS. In the RCT phase, repeated measures ANOVA with tDCS type [verum (N = 12) vs. sham (N = 13)] as between subjects factor demonstrated a significant tDCS-type X time-point interaction [F = 21.5, p. <. 0.001, partial-η2 = 0.48] with significantly greater reduction of AVH score in verum tDCS group as compared to sham group. In the OLE phase, sham-to-verum crossed over patients (N = 13) showed significantly greater reduction in AVH severity than their corresponding change during RCT phase (t = 2.9; p = 0.01). Together, these observations add further support to the beneficial effects of add-on tDCS to treat refractory AVH schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=85028516876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028516876&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2017.08.047

DO - 10.1016/j.schres.2017.08.047

M3 - Article

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -